Funding Amounts i. September 1, 2019: 1%
Funding Amounts. September 1, 2019: 1% (5,544.01 per FTE) • September 1, 2020: 1% ($5,599.45 per FTE) • September 1, 2021: 1% ($5,655.45 per FTE) Funding will be made retroactive to September 1, 2019.
Funding Amounts. 2.1 The Project Partner will provide funding for the Project in the minimum amount of EUR [amount], in accordance with the budget in the Project Proposal and the funding ratio of the Parties´ contributions contained therein.
Funding Amounts. Upon the occurrence of each Contribution Event (as defined below), Riviera Holdings shall pay, after receipt of the notice described in Sections 3 or 4 below, the applicable Funding Amounts (as defined below) into the Construction Disbursement Account for disbursement in accordance with the Cash Collateral and Disbursement Agreement. For the purposes of Sections 2(i), 2(ii) and 2(iii) below, the "Funding Amounts" shall be equal to the amount in immediately available cash determined by the Independent Construction Consultant, based upon the Construction Disbursement Budget, to be necessary to cause a Contribution Event to no longer exist; provided, however, that in no event shall the aggregate amount of all Funding Amounts paid pursuant hereto exceed $10,000,000; provided, further, that for purposes of Sections 2(iv), 2(v) and 2(vi) below, the Funding Amounts shall be equal to the difference between $10,000,000 and the aggregate Funding Amounts, if any, previously paid under Section 2. Such proceeds shall be used for the development, construction, equipping and operations of the Riviera Black Hawk pursuant to the terms of the Indenture, the Cash Collateral and Disbursement Agreement and the other Collateral Documents.
Funding Amounts. The Funding Amount for a Pool acquired on a Funding Date shall be determined by the Servicer on behalf of the Transferor and confirmed by the Certificate Funding Administrator and the Trustee and shall be reflected in the Funding Report with respect to Lease Contracts identified on the related Amended Lease Schedule attached to the Transferor Certificate and the Company Certificate for such Funding. Each additional Pool shall become subject to this Agreement pursuant to the Transferor's Certificate and the related Lease Contract Files shall be held by the Trustee as provided herein.
Funding Amounts. Arsanis shall pay Adimab for the FTEs actually performing scientific work in each Research Program under the Collaboration during the Collaboration Term at the FTE Rate; provided, however, that Arsanis will not be responsible to fund any Adimab FTEs in excess of an average of [**] per month during any [**]-month period of the Collaboration Term without Arsanis’ prior written consent. Adimab acknowledges and agrees that the FTE Rate reflects Adimab’s fully-loaded costs and expenses in performing its Research Program obligations under the Collaboration, and that Adimab is solely responsible for its internal and external costs and expenses in performing its obligations thereunder (provided that Adimab shall not be required to devote FTEs to the Research Programs which FTEs are not funded by Arsanis under this Section). During all accounting periods of the Target Nomination Period, Arsanis is required to pay Adimab for a minimum of [**] FTEs in such accounting period, even if Arsanis does not provide Targets such that there are Target Research Programs for such FTEs to work on or authorize Adimab to perform any “optional” research activities under a Research Plan as described in the last paragraph of Section 2.2(d).
Funding Amounts. Lender agrees to loan to Borrower the principal amount not to exceed Ninety Million Dollars ($90,000,000.00) (“Loan Commitment”). In consideration therefor, Borrower agrees to pay to Lender amounts equal to the principal and interest coming due on the Loan as and when due as provided herein. The Loan shall be designated the “$90,000,000 CMB Infrastructure Investment Group VII Loan”. The determination of all subsequent dates, such as the Maturity Date (as hereinafter defined) and the Prepayment Date (as hereinafter defined), shall be based upon the date of the disbursement of the initial advance by Lender to Borrower (the “Initial Funding”) pursuant to this Agreement (the date of such Initial Funding shall be referred to herein as the “Initial Funding Date”). The amount of the Initial Funding shall not be less than $80,000,000 (the “Minimum Initial Funding”). Each subsequent disbursement of loan proceeds by Lender to Borrower pursuant to this Agreement (each such disbursement, a “Tranche”) shall be made in the principal amount of $500,000 or any multiple thereof. Each Tranche shall be disbursed by Lender directly to Borrower or to an account designated by Borrower.
Funding Amounts. D.2 Table 1 sets out:
Funding Amounts. Funding Amounts shall be payable by Counterparty to UBS. Business Day Convention: [Modified Following] Business Days: London [Fixed Amounts: Notional Amount: Initial Dirty Proceeds Amount Fixed Rate: XXX per cent per annum Fixed Rate Day Count Fraction: Actual/365 (fixed)
Funding Amounts. Alector shall pay Adimab for the FTEs actually performing scientific work in each Research Program under the Collaboration during the Collaboration Term at the FTE Rate; provided, however, that Alector will not be responsible to fund any Adimab FTEs in excess of the FTE estimates set forth in a Research Plan without Alector’s prior written consent in its sole discretion and that in the absence of such consent, Adimab shall not be required to expend additional FTEs beyond those estimated in the applicable Research Plan. Adimab acknowledges and agrees that the FTE Rate reflects Adimab’s fully-loaded costs and expenses in performing its Research Program obligations under the Collaboration, and that except as explicitly set forth herein Adimab is solely responsible for its internal and external costs and expenses in performing its obligations thereunder (provided that Adimab shall not be required to devote FTEs to the Research Programs which FTEs are not funded by Alector under this Section). In addition, Alector shall reimburse Adimab for any external costs actually spent by Adimab related to the purchase or production of antigen for use in a Research Program, provided Adimab has obtained Alector’s prior written consent for any such external costs.
